Maintained active dialogue with the FDA throughout their substantive review of 510(k) application.

Advanced all tests in pipeline towards completion, regulatory submission, and commercialization.

Believe that COVID-19, tuberculosis, multiplex respiratory, and HPV multiplex tests on the Co-Dx PCR platform have the potential to increase access to state-of-the-art PCR diagnostics.

Team working hard to make mission a reality and drive test developments forward.